Ahren Innovation Capital is an investment institution that supports transformational companies at the intersection of deep tech and deep science that will penetrate, or create, massive markets.  Ahren is a unique partnership of investment talent and best-in-class commercial scientists whose technologies are today valued in excess of $100BN combined. Ahren believes in taking asymmetric, considered, risk that will deliver superior rewards – capturing a generational opportunity to provide smart capital to deep technology. With a philosophy espousing the importance of relationships and trust, Ahren provides both patient and active capital to exceptional founders and teams, empowering them to succeed.

Ahren Innovation Capital

Amadeus Capital is a global technology investor that invests in technology companies at all stages, from seed to venture buyout; they also buy stakes from other investors or founders, to ensure that companies and entrepreneurs have the runway they need to succeed. They invest in a broad variety of sectors including enterprise and infrastructure software, consumer and business services, medical technology and healthcare IT, and cleantech and resource efficiency. It has the imagination to see where new businesses can be created and the technical insight, operational experience and global network to help entrepreneurs make their vision a reality. The Company was founded in 1997 and since has backed more than 130 companies and raised over $1bn for investment.

Amadeus Capital Partners

OMX Ventures is investing at the convergence of biology and computing.

OMX Ventures

General Inception is an institutional co-founder for science-based companies bringing specialized expertise, operational resources and capital to innovation.

General Inception

Paladin Capital Group is a leading global investor that supports and grows the world’s most innovative companies through venture investment, expansion, and growth capital.  Paladin is a leader in investing in technologies, products, and services focused on dual use in both commercial and governmental markets with a strong value-add culture. The Paladin team merges financial expertise with national security and technical competence to add value across a wide array of market sectors and company stages. Paladin is focused on being an active investor—bringing decades of experience, advice, access, and relationships to its portfolio companies. Their most recent fund focuses on digital infrastructure resilience, investing globally in advanced technologies and solutions which enable, monitor, manage, and defend critical infrastructure that is dependent on cyber space.  The firm is headquartered in Washington, DC, with offices in New York City, Silicon Valley, London, and Luxembourg.

Paladin Capital Group

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

+ND Capital

Fine Structure Venture is an investment firm.

Fine Structure Venture

Constructive Bio

At Constructive Bio we rewrite the genome to build the biomolecules of the future. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.

Constructive Bio is a UK-based biotechnology specializing in synthetic biology, focusing on reprogramming the genetic code of living organisms and creating synthetic genomes from scratch. Constructive Bio's core technology is based on two proprietary platforms: large-scale DNA assembly and genome reprogramming. These technologies allow the company to construct large chunks of DNA, including whole bacterial genomes, and systematically recode genomes to engineer unnatural products for commercial applications.

Re-engineering biology, Constructive Bio scores $15 million to make new class of enzymes

Constructive Bio launched to build on synthetic biology breakthroughs

LifeArc Helps Create New MRC Spin-out Company

Constructive Bio targets sustainability with genome tech

Constructive Bio launches with £12.5m to rewrite DNA

Constructive Bio launches with $15M seed investment to re-engineer biology

Constructive Bio launches with $15m funding ‘to write entire genomes from scratch’

LifeArc helps create new MRC spin

Constructive Bio Strengthens Management Team and Board of Directors with Key Appointments to Accelerate Synthetic Genomics to Innovate Biologic Therapies

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Constructive Bio raises £43m ‘to turn living cells into biofactories’

Constructive Bio is a biotechnology company that specializes in rewriting genomes to create innovative biomolecules. Founded in 2022 and headquartered in Cambridge, UK, the company is based on groundbreaking research by Professor Jason Chin at the Medical Research Council Laboratory of Molecular Biology. Constructive Bio's core technology platforms focus on large-scale DNA assembly and genome reprogramming. These allow the company to synthesize whole bacterial genomes from scratch and systematically recode genomes to engineer unnatural products for commercial applications.
The company's technology enables the creation of new classes of enzymes, pharmaceuticals, and biomaterials. Constructive Bio has demonstrated the ability to program cells to produce novel molecules, including new types of drugs and synthetic polymers containing chemical linkages found in biodegradable plastics. A key achievement is the development of a re-engineered E. coli strain with an entirely synthetic genome that can assemble polymers from non-natural building blocks. This modified bacteria also exhibits resistance to a wide variety of viruses, which can potentially increase bio-manufacturing yields.
Constructive Bio aims to apply its technology across multiple industries, including therapeutics, agriculture, manufacturing, and materials science. The company is particularly focused on developing sustainable solutions, such as designing novel polymers that can break down and have their monomers recycled, potentially transforming the USD 750 billion global polymers market. The company has expanded its team and moved to a new state-of-the-art facility in South Cambridge to accelerate its research and development efforts.

Constructive Bio is a UK-based biotechnology specializing in synthetic biology, focusing on reprogramming the genetic code of living organisms and creating synthetic genomes from scratch. Constructive Bio's core technology is based on two proprietary platforms: large-scale DNA assembly and genome reprogramming. These technologies allow the company to construct large chunks of DNA, including whole bacterial genomes, and systematically recode genomes to engineer unnatural products for commercial applications.The company's approach enables the creation of organisms with remarkable properties, including resistance to a wide variety of viruses and the ability to produce new unnatural or synthetic polymers. Constructive Bio aims to synthesize polymers with non-natural amino acids for applications across various industries, including novel therapeutics, antibiotics, enhanced agriculture, manufacturing, and materials.&nbsp;&nbsp;Key customers and partnershipsIn September 2024, along with its launch, the company partnered with&nbsp;<a href="https://www.labiotech.eu/trends-news/biotech-company-constructive-bio-launched-in-uk/">Medical Research Council (MRC)</a>, obtaining an exclusive license from the MRC’s Laboratory of Molecular Biology to commercialize intellectual property developed by the laboratory. This partnership has formed the foundation of Constructive Bio's platform.

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

<div>
Constructive Bio has successfully raised a total of USD 58 million in the initial phase of its Series A funding, with participation from Ahren, OMX Ventures, and Paladin Capital Group. Other participants in the funding round include Fine Structure Ventures, +ND Capital, and Abcam's founder, Jonathan Milner. As a result of this financing round, the total amount raised by the company to date reaches USD 75 million. Ahren's representative has now taken a place on the board of directors of Constructive Bio. 

The newly secured funds will be used for the further evolution and refinement of the company's exclusive technology, planned for the creation of innovative biomolecules via the process of genome writing. 

Located in Cambridge, Constructive Bio is a leading biotechnology firm with a specialisation in the field of synthetic biology. The company primarily focuses on reprogramming the genetic code of living organisms and synthesising genomes from scratch, using two proprietary platforms. These include large-scale DNA assembly and genome reprogramming, which allow the company to build large strands of DNA, such as whole bacterial genomes, and systematically recode genomes. This invention process is aimed to generate new products for a variety of uses. 

</div>

Constructive Bio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless